<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89149">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02054052</url>
  </required_header>
  <id_info>
    <org_study_id>GZTO1401</org_study_id>
    <nct_id>NCT02054052</nct_id>
  </id_info>
  <brief_title>Intrapleural Bevacizumab Injection for Malignant Pleural Effusion in Lung Cancer</brief_title>
  <official_title>Intrapleural Bevacizumab Injection for Treating Malignant Pleural Effusion in Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haihong Yang, MD, Pricipal investigator</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Medical University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malignant pleural effusion (MPE) is common in lung cancer, and intrapleural drugs injection
      is important in the treatment. Non- cytotoxic drugs include those with a sclerosing effect
      that produces pleurodesis, which is easy to  cause severe chest pain despite of no influence
      on the following chemotherapy. Tumor angiogenesis is important in producing MPE. Bevacizumab
      has been administrated locally in treating optic nerve sickness successfully by anti-VEGF
      mechanism. So we hypothesize that intrapleural bevacizumab is also effective in treating
      MPE.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Lung cancer  symptom</measure>
    <time_frame>Evaluated by lung cancer symptom scale 21-30 days after the treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>Evaluate response rate 21-30 days after the treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>1 year after the treatment of MPE.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year after the treatment of MPE</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>one months after the treatment of MPE</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Malignant Pleural Effusion</condition>
  <arm_group>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab 100 mg, intrapleural injection treating MPE</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab 100 mg, intrapleural injection treating MPE after the drainage of MPE</description>
    <arm_group_label>Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histological or cytological diagnosis of non-small cell lung cancer.

          2. Cytological diagnosis of malignant pleural effusion (MPE)

          3. Symptomatic MPE evaluated by researchers

          4. Unsuitable for or reject systemic therapy of tumor

          5. Estimated survival of more than 3 months. 6.18 years or older

        Exclusion Criteria:

          1. Current or recent (within 10 days prior to treatment) use the full amount of
             inhibition of platelet function, anticoagulants or thrombolytic therapy, which allows
             prophylactic anticoagulants

          2. Be allergic to bevacizumab

          3. Pregnant or lactating woman

          4. Pleural infection
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haihong Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>the First Affiliated Hospital of Guangzhou MC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haihong Yang, MD</last_name>
    <phone>00862083062821</phone>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affliliated Hospital of Guangzhou MC</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haihong Yang, MD</last_name>
      <phone>00862083062821</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 1, 2014</lastchanged_date>
  <firstreceived_date>January 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou Medical University</investigator_affiliation>
    <investigator_full_name>Haihong Yang, MD, Pricipal investigator</investigator_full_name>
    <investigator_title>Deputy Chief Physician</investigator_title>
  </responsible_party>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>malignant pleural effusion</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>intrapleural injection</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
    <mesh_term>Pleural Effusion, Malignant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
